Fadogia Agrestis Benefits for Men: Dosage, Safety & Science (2026)

By Jordan Harvey · 16 June 2026 · Updated 16 June 2026 · 11 min read

Fadogia agrestis is a West African shrub that surged into the global supplement conversation after a 2005 rat study reported significant, dose-dependent testosterone increases at 18, 50, and 100mg/kg over five days (Yakubu et al., Asian J Andrology, 2005). The traditional Nigerian use as an aphrodisiac, the eye-catching numbers, and a high-profile podcast endorsement (Andrew Huberman, 2021) turned a niche herb into one of the most-searched testosterone supplements in the UK — before the rest of the picture caught up.

The rest of the picture is the part most product pages skip. The same research group that found the testosterone effect later documented irreversible testicular damage at 50mg/kg, and liver enzyme leakage at all tested doses. There are still zero published human clinical trials. This UK guide walks through what the animal research actually shows, what the safety signals mean at human-equivalent doses, how fadogia compares to Tongkat Ali (which has a meta-analysis), and how the two are sometimes stacked together — including a dedicated Tongkat Ali and Fadogia Agrestis stack analysis.

What Is Fadogia Agrestis and How Does It Work?

Fadogia agrestis is a flowering shrub in the Rubiaceae family, native to Nigeria, Ghana, and surrounding parts of West Africa. It grows to roughly 1–2 metres and is characterised by yellow tubular flowers and bright orange-red berries. The medicinal part is the stem, which is dried, powdered, and traditionally prepared as a water-based decoction used as an aphrodisiac and treatment for erectile complaints in northern Nigerian herbal medicine.

The plant’s phytochemistry is dominated by quinoline and isoquinoline alkaloids, alongside saponins, tannins, anthraquinones, and flavonoids. The 2005 testosterone effect was attributed primarily to the saponin-rich aqueous fraction, with a hypothesised mechanism of action loosely modelled on androgen-receptor agonism — though the receptor-binding studies that would confirm this have never been published in human cells. The same alkaloid class implicated in the testosterone effect appears to drive the toxicity signal: lipid peroxidation in plasma membranes of liver, kidney, and Leydig cells.

The key practical fact: every claim about what fadogia does in men is extrapolated from a small animal-study literature. There is no human pharmacokinetic data, no human dose-response data, and no human safety data of any duration. That is unusual even by herbal-supplement standards, and it changes how the rat findings should be read.

What Does the Animal Research Actually Show?

1. Testosterone & Aphrodisiac Effects (2005) Animal Only

In a 5-day study on male albino rats, fadogia agrestis aqueous stem extract at 18, 50, and 100mg/kg body weight produced significant, dose-dependent increases in serum testosterone, alongside increased mounting frequency and intromission frequency — standard rodent proxies for sexual motivation (Yakubu et al., Asian Journal of Andrology, 2005). This is the study that generated essentially all of the initial commercial excitement and the “multi-fold testosterone increase” talking point that still appears on product pages today.

2. Testicular Toxicity (2008) Critical Safety Data

In a 28-day rat study using the same dose range, the picture changed sharply. At 50mg/kg body weight (human equivalent ~607mg/day for a 70kg adult), fadogia caused irreversible disintegration of the seminiferous tubules with loss of germ-cell attachment to the basement membrane — the architecture in which sperm is actually produced. The 100mg/kg group showed even more severe damage. At the lowest dose tested (18mg/kg, HED ~218mg), changes were milder and reversed after a 10-day recovery period (Yakubu et al., J Ethnopharmacol, 2008).

3. Liver and Kidney Toxicity (2009)

The follow-up study examined hepatic and renal markers across the same three doses over 28 days. At all tested doses, including the lowest, liver enzyme leakage into serum (ALT/AST elevation) was detected, indicating hepatocyte membrane damage. Serum malondialdehyde, a marker of oxidative stress, rose significantly at all doses. The proposed mechanism was lipid peroxidation driven by quinoline and isoquinoline alkaloids damaging plasma membranes of liver and kidney cells (Yakubu et al., Hum Exp Toxicol, 2009). The lowest tested dose (HED ~218mg) was already producing measurable liver stress.

4. SSRI-Induced ED Model (2022)

A more recent rat study explored fadogia’s effect on erectile function in animals previously exposed to SSRIs (a model of pharmacologically induced ED). Fadogia partially restored several markers (Ogunro & Yakubu, Reproductive Sciences, 2022). It is interesting mechanistically but does not change the safety picture, and it remains a rat model.

Study Funding & Independence

Fadogia’s evidence base is small enough that the funding profile of every study matters:

All published fadogia work is independent — there is no Biotropics-equivalent industry sponsor pushing a standardised extract. That is, in some ways, an advantage (less publication bias). It also means the supportive literature has not grown beyond a handful of papers from largely the same research group.

Fadogia Forms, Quality & the Adulteration Problem

Even men who decide the rat data is sufficient face a second problem: getting an actual fadogia product. Researchers at the University of Mississippi’s National Center for Natural Products Research tested 17 commercial fadogia agrestis supplements sold in the UK and US market. Their findings were stark: 5 out of 17 (29%) contained zero detectable fadogia compounds, and the remaining products had phenolic content ranging from just 0.3 to 2.7mg per daily serving (Avula et al., Planta Medica, 2019). UK retail prices range from £8 to £37 with no guarantee that anything fadogia-derived is actually in the capsule.

In other words: the supplement category most commonly sold for fadogia is one in which there is no agreed standardisation marker, no human safety data, and a documented 29% “blank” rate at retail. That is a very different proposition from a category like Shilajit or Tongkat Ali, where standardisation, third-party testing, and a meta-analysis exist.

How Much Fadogia Agrestis Should Men Take? Dosage Guidance

There is no clinically established human dose. Manufacturers and podcasters extrapolate from the 18mg/kg rat dose using FDA allometric scaling (which divides by ~6.2 to convert rat mg/kg to human mg/kg) to arrive at ~218mg/day for a 70kg man as a notional “low” dose. Some product labels suggest 600mg/day, which corresponds to the 50mg/kg rat dose at which testicular toxicity was documented. Three honest observations:

• The lowest extrapolated “effective” dose (~218mg/day) is also where rat liver toxicity was already detectable. There is no margin of safety established in the literature.
• Cycling claims (8 weeks on / 4 off) have no human evidence. They are precautionary, not validated.
• Without standardisation, equal “mg” from different brands are not equal. The Avula 2019 finding is decisive on this point.

Are There Side Effects or Safety Concerns?

The published animal data identifies three concrete signals that men should weigh against the appeal of the testosterone numbers: testicular damage at moderate doses, liver enzyme leakage at every tested dose, and oxidative stress markers rising in lock-step with dose. The bigger absence is what is missing — there is no human clinical safety dataset to compare against. Anecdotal user reports include digestive discomfort, headaches, irritability, and sleep disturbance, but anecdote is not a substitute for a 9-month placebo-controlled trial.

Momentous, the supplement brand co-founded with Dr Andrew Huberman, discontinued its standalone fadogia product in 2024, citing “evolving research” on safety. That decision did not make the news cycle in the way the original 2021 podcast appearance did, but it is one of the more telling data points in the category.

How to Choose Quality Fadogia Agrestis in the UK (If You Still Want To)

The honest version: it is currently not possible to verify a fadogia product in the way you can verify Tongkat Ali (eurycomanone %) or Shilajit (fulvic acid %). What you can do is reduce the risk of buying nothing:

• Demand a Certificate of Analysis covering identity (HPTLC or HPLC fingerprinting), heavy metals, microbial contamination, and an FDA-aligned adulterant screen. If the brand cannot or will not provide one, the Avula 2019 results are your prior.
• GMP certification (UK or EU) as the floor — not the ceiling.
• UK-registered company with a real address and accountable returns policy.
• No proprietary blends. The fadogia mg should be on the label, not bundled into a “Men’s Vitality Matrix”.
• Honest copywriting. Any brand citing “multi-fold testosterone increase” without saying “in rats over five days” is failing a basic transparency test.

Why Does Blue Power Use Tongkat Ali Instead of Fadogia Agrestis?

For the specific question of stacking the two ingredients, our dedicated Tongkat Ali and Fadogia Agrestis deep-dive walks through the popular “Huberman stack” protocol, the cycling claims, and what the evidence actually supports.

Frequently Asked Questions About Fadogia Agrestis

The Bottom Line: Should Men Take Fadogia Agrestis?

Fadogia agrestis sits at an unusual point on the supplement evidence map: a single five-day rat study generated almost all of its commercial momentum, while every follow-up study from the same research group has documented organ toxicity at the same doses. There are no human RCTs. The supplement category itself has a 29% blank rate at retail. Momentous, the brand most associated with the ingredient’s mainstream popularity, has discontinued it.

None of that proves fadogia is dangerous in humans — rat lipid peroxidation does not always translate, and clinical-trial confirmation could yet emerge. But for a UK man weighing supplements in 2026, the honest comparison is not “does fadogia work?” but “is fadogia the best use of my evidence-adjusted budget?”. Against an alternative with a 2022 meta-analysis of 5 human RCTs (Tongkat Ali) and an alternative with published human RCT data (Shilajit), the starting point for evidence-led decision-making is clear.

If, after weighing all of this, you still want to try fadogia, do it with eyes open: lowest available dose, baseline liver markers from your GP, no longer than 8 weeks, and only from a brand that publishes a Certificate of Analysis. Skip the proprietary blends.